Cargando…

Exposure‐Safety Analyses Identify Predictors of Change in Bone Mineral Density and Support Elagolix Labeling for Endometriosis‐Associated Pain

Elagolix is a novel oral gonadotropin releasing hormone receptor antagonist, that can suppress estradiol in a dose‐dependent manner. It is indicated for management of moderate‐to‐severe pain associated with endometriosis. A population exposure‐response model describing the relationship between elago...

Descripción completa

Detalles Bibliográficos
Autores principales:	Abbas Suleiman, Ahmed, Nader, Ahmed, Winzenborg, Insa, Beck, Denise, Polepally, Akshanth R., Ng, Juki, Noertersheuser, Peter, Mostafa, Nael M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7679073/ https://www.ncbi.nlm.nih.gov/pubmed/32945631 http://dx.doi.org/10.1002/psp4.12560

Ejemplares similares

Effect of Elagolix Exposure on Clinical Efficacy End Points in Phase III Trials in Women With Endometriosis‐Associated Pain: An Application of Markov Model
por: Winzenborg, Insa, et al.
Publicado: (2020)

Validation of a quantitative systems pharmacology model of calcium homeostasis using elagolix Phase 3 clinical trial data in women with endometriosis
por: Stodtmann, Sven, et al.
Publicado: (2021)

Clinical Pharmacology of Elagolix: An Oral Gonadotropin-Releasing Hormone Receptor Antagonist for Endometriosis
por: Shebley, Mohamad, et al.
Publicado: (2019)

Population Pharmacokinetics of Elagolix in Combination with Low-Dose Estradiol/Norethindrone Acetate in Women with Uterine Fibroids
por: Beck, Denise, et al.
Publicado: (2021)

Assessment of Clinical Drug‐Drug Interactions of Elagolix, a Gonadotropin‐Releasing Hormone Receptor Antagonist
por: Polepally, Akshanth R., et al.
Publicado: (2020)

Interdisciplinary model‐informed drug development for extending duration of elagolix treatment in patients with uterine fibroids
por: Beck, Denise, et al.
Publicado: (2022)

Integrating real‐world data and modeling to project changes in femoral neck bone mineral density and fracture risk in premenopausal women
por: Beck, Denise, et al.
Publicado: (2021)

Effects of elagolix on the pharmacokinetics of omeprazole and its metabolites in healthy premenopausal women
por: Nader, Ahmed, et al.
Publicado: (2022)

Exposure–Response Analyses of Upadacitinib Efficacy and Safety in Phase II and III Studies to Support Benefit–Risk Assessment in Rheumatoid Arthritis
por: Nader, Ahmed, et al.
Publicado: (2019)

Elagolix in the treatment of endometriosis: impact beyond pain symptoms
por: Archer, David F., et al.
Publicado: (2020)

A Clinician's Guide to the Treatment of Endometriosis with Elagolix
por: Leyland, Nicholas, et al.
Publicado: (2021)

Health-Related Quality of Life Improvements in Patients With Endometriosis Treated With Elagolix
por: Taylor, Hugh S., et al.
Publicado: (2020)

Quantitative Assessment of Elagolix Enzyme-Transporter Interplay and Drug–Drug Interactions Using Physiologically Based Pharmacokinetic Modeling
por: Chiney, Manoj S., et al.
Publicado: (2019)

Exposure–Response Relationships for Efficacy and Safety of Risankizumab in Phase II and III Trials in Psoriasis Patients
por: Khatri, Amit, et al.
Publicado: (2019)

Pharmacokinetic and Pharmacodynamic Profiles of Ethinylestradiol/Norgestimate Combination or Norethindrone upon Coadministration with Elagolix 150 mg Once Daily in Healthy Premenopausal Women
por: Feldman, Robert A., et al.
Publicado: (2021)

Phase 2, double-blind, randomized, placebo-controlled study of the safety and efficacy of elagolix in women with polycystic ovary syndrome
por: Snabes, Michael C., et al.
Publicado: (2023)

Elagolix: a promising oral GnRH antagonist for endometriosis-associated pain
por: Dun, Erica C., et al.
Publicado: (2017)

Real-World Characterization of Women with Diagnosed Endometriosis Initiating Therapy with Elagolix Using a US Claims Database
por: Surrey, Eric S, et al.
Publicado: (2020)

Endometriosis-Related Pain Reduction During Bleeding and Nonbleeding Days in Women Treated with Elagolix
por: Agarwal, Sanjay K, et al.
Publicado: (2021)

Elagolix, an Oral GnRH Antagonist for Endometriosis-Associated Pain: A Randomized Controlled Study
por: Carr, Bruce, et al.
Publicado: (2013)

Elagolix: First Global Approval
por: Lamb, Yvette N.
Publicado: (2018)

Correction to: Elagolix: First Global Approval
por: Lamb, Yvette N.
Publicado: (2018)

A Personalized Medicine Approach Using Clinical Utility Index and Exposure‐Response Modeling Informed by Patient Preferences Data
por: Winzenborg, Insa, et al.
Publicado: (2020)

Impact of Elagolix on Workplace and Household Productivity Among Women with Moderate to Severe Pain Associated with Endometriosis: A Pooled Analysis of Two Phase III Trials
por: Surrey, Eric S., et al.
Publicado: (2019)

Estimating the Effect of Elagolix Treatment for Endometriosis on Postmenopausal Bone Outcomes: A Model Bridging Phase III Trials to an Older Real‐World Population
por: Kilpatrick, Ryan D, et al.
Publicado: (2020)

The role of elagolix in the suppression of ovulation in donor oocyte cycles
por: Boniface, Catherine, et al.
Publicado: (2023)

Elagolix: How far can it go in the world of gynecology?
por: Danis, Rachel B.
Publicado: (2023)

Reductions in endometriosis-associated pain among women treated with elagolix are consistent across a range of baseline characteristics reflective of real-world patients
por: Abrao, Mauricio S., et al.
Publicado: (2021)

Clinical development of the oral gonadotropin-releasing hormone antagonist elagolix
por: Chwalisz, Kristof
Publicado: (2023)

Greenness assessment of micellar spectrofluorometric approach for determination of Elagolix: application to dosage form, content uniformity and human plasma
por: Ahmed, Rasha M.
Publicado: (2021)

Does timing matter when initiating elagolix in a natural menstrual cycle?
por: Danis, Rachel B., et al.
Publicado: (2021)

Elagolix is porphyrogenic and may induce porphyric attacks in patients with the acute hepatic porphyrias
por: Ma, Christopher D., et al.
Publicado: (2022)

Elagolix Treatment for Up to 12 Months in Women With Heavy Menstrual Bleeding and Uterine Leiomyomas
por: Simon, James A., et al.
Publicado: (2020)

Efficacy and safety of elagolix with add-back therapy in women with uterine fibroids and coexisting adenomyosis
por: Muneyyirci-Delale, Ozgul, et al.
Publicado: (2021)

Elagolix Sodium Salt and Its Synthetic Intermediates: A Spectroscopic, Crystallographic, and Conformational Study
por: Ciceri, Samuele, et al.
Publicado: (2023)

Dosing Recommendations for Concomitant Medications During 3D Anti-HCV Therapy
por: Badri, Prajakta S., et al.
Publicado: (2015)

Ultra-sensitive and selective fluorescence approach for estimation of elagolix in real human plasma and content uniformity using boron-doped carbon quantum dots
por: Salman, Baher I., et al.
Publicado: (2022)

Predictors of response for elagolix with add-back therapy in women with heavy menstrual bleeding associated with uterine fibroids
por: Al-Hendy, Ayman, et al.
Publicado: (2021)

Clinical Utility Of Elagolix As An Oral Treatment For Women With Uterine Fibroids: A Short Report On The Emerging Efficacy Data
por: Neri, Manuela, et al.
Publicado: (2019)

Elagolix treatment in women with heavy menstrual bleeding associated with uterine fibroid: a systematic review and meta-analysis
por: Muhammad, Juliawati, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_7gdp8mjb0dh5bp1a5hb17b4u1k